Stock Scorecard



Stock Summary for Scholar Rock Holding Corp (SRRK) - $42.76 as of 1/5/2026 9:11:37 PM EST

Total Score

6 out of 30

Safety Score

43 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SRRK

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SRRK

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SRRK

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SRRK

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SRRK (43 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for SRRK

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears 12/30/2025 9:08:00 PM
Scholar Rock Holding Corporation $SRRK Shares Bought by Voya Investment Management LLC 12/23/2025 2:09:00 PM
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 13, 2025 12/15/2025 2:10:00 PM
Scholar Rock (NASDAQ: SRRK) grants 7,800-share inducement awards at $45.25 exercise price 12/13/2025 4:09:00 PM
Scholar Rock stock rating reiterated as Overweight by Cantor Fitzgerald 12/11/2025 2:08:00 PM
Scholar Rock stock reaches 52-week high at 47.01 USD 12/10/2025 11:08:00 AM
Scholar Rock (SRRK) Valuation Revisited After FDA Warning Letter to Key Manufacturing Partner 12/6/2025 4:43:00 AM
Scholar Rock Holding Corporation $SRRK Position Cut by Fisher Asset Management LLC 12/5/2025 4:43:00 AM
FDA Manufacturing Letter And Backup Plant Plans Could Be A Game Changer For Scholar Rock (SRRK) 12/4/2025 4:43:00 AM
Scholar Rock Updates on FDA Warning and Apitegromab Launch Plans 12/3/2025 4:43:00 AM

Financial Details for SRRK

Company Overview

Ticker SRRK
Company Name Scholar Rock Holding Corp
Country USA
Description Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing targeted therapies that utilize the TGF-beta superfamily of proteins to address serious diseases. Its robust pipeline focuses on critical conditions, including muscular dystrophy and various cancers, illustrating the company's commitment to improving patient outcomes through innovative scientific research. By fostering strategic collaborations, Scholar Rock accelerates the advancement of its pioneering treatment modalities, establishing itself as a significant force in the biopharmaceutical sector.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 42.76
Price 4 Years Ago 9.05
Last Day Price Updated 1/5/2026 9:11:37 PM EST
Last Day Volume 1,197,313
Average Daily Volume 1,330,510
52-Week High 48.28
52-Week Low 22.71
Last Price to 52 Week Low 88.29%

Valuation Measures

Trailing PE N/A
Industry PE 21.56
Sector PE 52.63
5-Year Average PE -10.50
Free Cash Flow Ratio 15.22
Industry Free Cash Flow Ratio 20.87
Sector Free Cash Flow Ratio 30.62
Current Ratio Most Recent Quarter 6.30
Total Cash Per Share 2.81
Book Value Per Share Most Recent Quarter 2.47
Price to Book Ratio 18.34
Industry Price to Book Ratio 4.22
Sector Price to Book Ratio 38.88
Price to Sales Ratio Twelve Trailing Months 13.14
Industry Price to Sales Ratio Twelve Trailing Months 30.90
Sector Price to Sales Ratio Twelve Trailing Months 11.30
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 102,007,000
Market Capitalization 4,361,819,320
Institutional Ownership 119.12%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -48.56%
Reported EPS 12 Trailing Months -3.15
Reported EPS Past Year -2.55
Reported EPS Prior Year -2.46
Net Income Twelve Trailing Months -353,427,999
Net Income Past Year -246,294,000
Net Income Prior Year -165,789,000
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 286,770,000
Total Cash Past Year 177,878,000
Total Cash Prior Year 101,855,000
Net Cash Position Most Recent Quarter 187,159,000
Net Cash Position Past Year 127,732,000
Long Term Debt Past Year 50,146,000
Long Term Debt Prior Year 48,684,000
Total Debt Most Recent Quarter 99,611,000
Equity to Debt Ratio Past Year 0.88
Equity to Debt Ratio Most Recent Quarter 0.71
Total Stockholder Equity Past Year 368,634,000
Total Stockholder Equity Prior Year 225,218,000
Total Stockholder Equity Most Recent Quarter 244,995,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -274,644,000
Free Cash Flow Per Share Twelve Trailing Months -2.69
Free Cash Flow Past Year -201,047,000
Free Cash Flow Prior Year -145,297,000

Options

Put/Call Ratio 0.31
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.61
MACD Signal 2.11
20-Day Bollinger Lower Band 24.59
20-Day Bollinger Middle Band 37.06
20-Day Bollinger Upper Band 49.53
Beta 0.62
RSI 52.38
50-Day SMA 35.28
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 1/3/2026 8:27:35 AM EST